LSTA Stock Analysis: Buy, Sell, or Hold?
LSTA - Lisata Therapeutics, Inc. Common Stock
$5.01
-0.01 (-0.20%)
▼
5d:
-0.2%
30d:
+22.2%
90d:
+154.31%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When LSTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LSTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LSTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LSTA is currently trading at $5.01, which is considered slightly high relative to its 30-day fair value range of $4.39 to $5.08.
Technical Outlook: Technically, LSTA is in a strong uptrend. The price is currently testing key support at $5.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LSTA is in a strong uptrend. The price is currently testing key support at $5.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+89.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$4.39 -
$5.08
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 89.6% below Wall St target ($9.50)
Fair Price Analysis
30-Day Fair Range
$4.39 -
$5.08
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.00
Resistance Level
$5.05
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.59
Wall Street Target
$9.50
(+89.6%)
Revenue Growth (YoY)
-90.0%
Share & Embed Analysis
Last updated: March 30, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LSTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 67 BUY |
